Results 171 to 180 of about 9,044,537 (408)

The effect of ICU-tailored drug-drug interaction alerts on medication prescribing and monitoring: protocol for a cluster randomized stepped-wedge trial [PDF]

, 2019
Tinka Bakker, Joanna E. Klopotowska, Saeid Eslami, Dylan W. de Lange, Rob J. van Marum, Heleen van der Sijs, Evert de Jonge, Dave A. Dongelmans, N. F. de Keizer, Ameen Abu‐Hanna   +9 more
openalex   +1 more source

Isavuconazole therapeutic drug monitoring in critically ill ICU patients: A monocentric retrospective analysis

, 2022
Rainer Höhl, Ralph Bertram, Martina Kinzig, Golo‐Sung Haarmeyer, Matthias Baumgärtel, Arnim Geise, Dorothea Muschner, Doris Prosch, Mira Reger, Hans‐Theodor Naumann, Joachim H. Ficker, Jens C. Kubitz, Joerg Steinmann, Fritz Sörgel   +13 more
openalex   +1 more source

Screening for lung cancer: A systematic review of overdiagnosis and its implications

Molecular Oncology, EarlyView.
Low‐dose computed tomography (CT) screening for lung cancer may increase overdiagnosis compared to no screening, though the risk is likely low versus chest X‐ray. Our review of 8 trials (84 660 participants) shows added costs. Further research with strict adherence to modern nodule management strategies may help determine the extent to which ...
Fiorella Karina Fernández‐Sáenz, Laura de la Torre‐Perez, David R Baldwin, Carlijn van der Aalst, Mangesh Thorat, David Ritchie, Andre L Carvalho, Carolina Espina, Ivan Solà, Carlos Canelo‐Aybar, Moira Magdalena Pissinis, Pablo Alonso‐Coello, Ana Carolina Pereira Nunes Pinto   +12 more
wiley   +1 more source

Towards Strengthened Preparedness and Response to New Psychoactive Substances in Europe

Emerging Trends in Drugs, Addictions, and Health
In January 2022, the European Commission proposed to strengthen the mandate of the EMCDDA, transforming it into the new EU Drugs Agency (EUDA) [1]. This new regulation aims to improve data sharing, preparedness, surveillance, risk assessment, early ...
A. Gallegos
doaj   +1 more source

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

A Calorimetric Study on Diflunisal Release from Poly(Lactide-co-Glycolide) Microspheres by Monitoring the Drug Effect on Dipalmitoylphosphatidylcholine Liposomes: Temperature and Drug Loading Influence [PDF]

, 2000
Francesco Castelli, Paolo Giunchedi, Olga La Camera, U. Conte   +3 more
openalex   +1 more source

Tacrolimus Therapeutic Drug Monitoring in Kidney Transplant Patients Before and After Pharmacist Post-transplant Consults

, 2021
Gabriella Massoglia, Michael J. Schuh
openalex   +2 more sources

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Supplementary Figure Legends from Real-time Fluorescent Resonance Energy Transfer Analysis to Monitor Drug Resistance in Chronic Myelogenous Leukemia

, 2023
Ahmet Tunceroglu, Michiyuki Matsuda, Raymond B. Birge   +2 more
openalex   +1 more source